Table 1 Relationship of TRIM36 expression and clinicopathologic characteristics of patients

From: TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways

Variable TRIM36 expression
  Negative (n = 31) Positive (n = 64) P value
Age    0.605
 <60 3 3  
 60–70 14 28  
 >70 14 33  
Preoperative PSA (ng/ml)    0.649
 <10 7 20  
 10–20 10 20  
 >20 14 24  
Gleason score    0.005
6 or =3+4 12 44  
 =4+3 or 8 19 20  
T stage    0.950
 pT2 26 54  
 pT3/ T4 5 10  
Biochemical recurrence    0.001
 Negative 12 48  
 Positive 19 16  
  1. Bold values signify P < 0.05. P values were two-tailed and based on the Pearson chi-square test